Newest Oldest Showing 21-40 of 50 results
Original Article / VOLUME 3, ISSUE 3, DECEMBER 2021

All-Cause Excess Mortality in 2020: The Example of Bursa City in Turkey

Kayıhan Pala and others

Estimations about confirmed COVID-19 deaths may be limited to the testing capacity and frequency, along with correct and complete reporting of the cause of deaths (1). The number of confirmed and probable COVID-19 deaths may not include people who (...) Read More

Commentary / VOLUME 3, ISSUE 3, DECEMBER 2021

Virtual Learning Opportunity During COVID-19 Pandemic: Comparison of Virtual (2021) and Face to Face (2019) Conferences of Turkish Society of Clinical Microbiology and Infectious Diseases

Önder Ergönül and others

About the last 10-year if not older, electronic learning as a training method in infectious diseases (ID) and clinical microbiology (CM) was defined as an area to be improved. In a survey published in 2017 by the European Society of Clinical Microbiology (...) Read More

Original Article / VOLUME 3, ISSUE 2, AUGUST 2021

The Effects of Polypharmacy, Nutritional and Functional Status on the Progression of COVID-19 in Older Adults

Asiye Bahar Kaçmaz and others

The SARS-CoV-2 infection has influenced the whole world and every day, both the number of cases and deaths related to the COVID-19 pandemic continue to rise. Eighty-one percent of COVID-19 cases are mild, 14% are serious and 5% are critical. Although the overall mortality rate was 2.3%, mortality (...) Read More

Original Article / VOLUME 3, ISSUE 2, AUGUST 2021

Infectivity of Adult and Pediatric COVID-19 Patients

Mahir Kapmaz and others

The clinical findings of SARS-CoV-2 infection are heterogeneous, and the duration of viral RNA shedding varies on the age of the patient, severity of the disease, and type of the sample. For that reason, a comprehensive analysis of the dynamics of viral shedding is critical for (...) Read More

Original Article / VOLUME 3, ISSUE 2, AUGUST 2021

Predictors of COVID-19 among Healthcare Workers who were Exposed to COVID-19

Çiğdem Erol and others

SARS-CoV-2 is transmitted via the inhalation of infected droplets or through direct contact with contaminated surfaces. Aerosol-generating procedures can also lead to airborne transmission. Healthcare workers (HCWs) are at higher risks for infections than the general (...) Read More

Case Report / VOLUME 3, ISSUE 2, AUGUST 2021

First Report of SARS-CoV-2 Gamma Variant in Turkey

Mert Ahmet Kuşkucu and others

As viruses spread through a population, they mutate and change, leading to the evolution of slightly different forms or variants. SARS-CoV-2 has been mutating ever since it was first detected in Wuhan, China, in December 2019. While most of the mutations will not have a significant effect on the spread of the virus, some mutations or (...) Read More

Case Report / VOLUME 3, ISSUE 2, AUGUST 2021

Two Cases of COVID-19 Reinfection in Turkey

İrem Akdemir-Kalkan and others

SARS-CoV-2 has affected the whole world while the number of cases is increasing rapidly. Several reinfection cases have been reported with the rise in the number of infected people. It is important to study these reinfection cases as the knowledge gained can be used in critical decisions (...) Read More

Original Article / VOLUME 3, ISSUE 1, APRIL 2021

Persistent Symptoms After Discharge of COVID-19 Patients

Oğuz Evlice and others

Introduction More than a year has passed since the beginning of the COVID-19 pandemic, and we are learning more about the long-term effects of the disease. While many patients recover completely, some continue to experience fatigue, dyspnea, cough, joint pain, and chest pain for weeks or even months (1).The UK National Institute for Health and […] Read More

Commentary / VOLUME 3, ISSUE 1, APRIL 2021

The Impact of SARS-CoV-2 Variants on Morbidity, Mortality and Effectiveness of Vaccines

Kenan Midilli

Coronaviruses are known to evolve slower than the other RNA viruses; however, SARS-CoV-2 underwent a major shift through D614G change in February 2020, even before the declaration of a pandemic by WHO and D614G variant became rapidly dominant throughout the world.  The spike protein of this variant with D614G change have a higher affinity to […] Read More

Visual Case Presentation / VOLUME 2, ISSUE 3, DECEMBER 2020

A COVID-19 Patient Which is Diagnosed after Magnetic Resonance Imaging

Uğur Kesimal

A 40-year-old female patient without any medical history presented to the emergency department with a 3-day history of neck pain and headache. She did not show any other symptoms. Her initial laboratory tests showed slightly increased C-reactive protein (6 mg/L; normal range 0-5 mg/L) and a normal white cell count. There were Read More

Letter to the Editor / VOLUME 2, ISSUE 3, DECEMBER 2020

Contaminated Generic Non-approved Remdesivir Vials: New Risk in Treatment of COVID-19

Gökhan Aygün and others

Remdesivir is a novel nucleotide analogue antiviral drug with in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). Food and Drug Administration (FDA) and Drug Controller General of India have authorized the emergency use for the treatment of COVID-19 under an Read More

Letter to the Editor / VOLUME 2, ISSUE 3, DECEMBER 2020

Relapse of Immune Thrombocytopenic Purpura in a Patient With COVID-19

Güldane Cengiz Seval and others

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as a global pandemic and worldwide confirmed cases are currently approaching 76 million. And so far, thrombocytopenia has been observed in 5% of hospitalized COVID-19 patients and 8% of those in intensive care unit. Although the decrease in platelet counts was mild, confirmation of immune etiology has to be confirmed in those with Read More